Stocktoria
KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $95.1M at a -138.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 1.7 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.735 |
| Retained earnings / assets | -1.759 |
| EBIT / assets | -0.36 |
| Equity / liabilities | 2.274 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| NPCE | NeuroPace Inc | 5/9 | -13.13 | — | +25.1% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
| IRMD | IRADIMED CORP | 5/9 | 14.84 | 53.4 | +14.4% |
| TELA | TELA Bio, Inc. | 3/9 | -13.97 | — | +15.8% |
About KESTRA MEDICAL TECHNOLOGIES, LTD.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
FAQ
Is KMTS financially healthy?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does KMTS pay a dividend?
No, KESTRA MEDICAL TECHNOLOGIES, LTD. does not currently pay a dividend.
How profitable is KMTS?
In FY2025, KESTRA MEDICAL TECHNOLOGIES, LTD. had a net margin of -138.4% and a return on equity of -50.7%.
What is the analyst price target for KMTS?
The average Wall-Street price target for KESTRA MEDICAL TECHNOLOGIES, LTD. is $27.71, about 1.0% below the recent price, from 7 analysts.
Is KMTS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on KESTRA MEDICAL TECHNOLOGIES, LTD.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.